LABD
NAV (Net Asset Value)$6.57As of Mar 07, 2024
1 Day NAV change$+0.26(+4.15%)As of Mar 07, 2024
LABU
NAV (Net Asset Value)$152.52As of Mar 07, 2024
1 Day NAV change$-6.58(-4.14%)As of Mar 07, 2024
LABDDirexion Daily S&P Biotech Bear 3X Shares
Operational Updates
- 01/23/2024
Direxion's New ETF Alert Service. Get Price and Volume Alerts automatically via text message!
Set Up Your ETF Alerts Today - 11/06/2023
Direxion Announces Reverse Splits of TMF and LABU
Read the Article
Documents & Downloads
- LABU LABD Fact Sheet (pdf)
- Direxion ETFs List (pdf)
- LABU Prospectus
- LABD Prospectus
- Daily Fund Holdings (csv)
These leveraged ETFs seek a return that is 300% or -300% of the return of their benchmark indexfor a single day.The funds should not be expected to provide three times or negative three times the return of the benchmark’s cumulative return for periods greater than a day.
Pricing & Performance
NAV and Market Price information as of 03/07/2024.
LABD
Direxion Daily S&P Biotech Bear 3X Shares
Net Asset Value (NAV)
$6.57Nav
$+0.26Change
+4.15%Change
Market Price Closing
$6.58Market
$+0.26Change
+4.11%Change
Premium / Discount
$+0.01Change from Last Day Trading
Premium/Discount tool
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Net Asset Value (NAV)
$152.52Nav
$-6.58Change
-4.14%Change
Market Price Closing
$152.45Market
$-6.49Change
-4.08%Change
Premium / Discount
$-0.07Change from Last Day Trading
Premium/Discount tool
Loading chart...
1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Since Inception | Expense Ratio* (Gross / Net%) | Inception Date | |
---|---|---|---|---|---|---|---|---|---|---|
LABD NAV | 1M -33.33 | 3M -60.18 | YTD -30.93 | 1Y -58.34 | 3Y -29.06 | 5Y -55.49 | 10Y — | Since -55.13 | Expense Ratio* 1.10 / 1.09* | Inception 05/28/2015 |
LABD Market Close | 1M -33.30 | 3M -60.21 | YTD -30.96 | 1Y -58.52 | 3Y -29.06 | 5Y -55.51 | 10Y — | Since -55.14 | Expense Ratio* 1.10 / 1.09* | Inception 05/28/2015 |
LABU NAV | 1M 36.05 | 3M 97.20 | YTD 24.25 | 1Y 15.76 | 3Y -58.98 | 5Y -33.55 | 10Y — | Since -29.30 | Expense Ratio* 1.01 / 1.01* | Inception 05/28/2015 |
LABU Market Close | 1M 35.81 | 3M 96.63 | YTD 24.24 | 1Y 15.75 | 3Y -59.01 | 5Y -33.55 | 10Y — | Since -29.31 | Expense Ratio* 1.01 / 1.01* | Inception 05/28/2015 |
As of February 29, 2024
The Primary Listing Exchange is the NYSE Arca, Inc.
*The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio would be 0.95%. The Funds’ adviser, Rafferty Asset Management, LLC (“Rafferty”), has entered into an Operating Expense Limitation Agreement with each Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse the Funds for Other Expenses through September 1, 2024, to the extent that a Fund’s Total Annual Fund Operating Expenses exceed 0.95% of the Fund’s average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. Returns for performance under one year are cumulative, not annualized. For the most recent month-end performance please visit the funds’ website at direxion.com.
Short-term performance, in particular, is not a good indication of a fund’s future performance, and an investment should not be made based solely on returns. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. For additional information, see the fund’s prospectus.
Index Information
The S&P Biotechnology Select Industry Index (SPSIBITR) is provided by S&P Dow Jones Indices LLC and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). One cannot invest directly in an index.
Index Top Ten Holdings
% of Total | |
---|---|
Cytokinetics | % of Total 2.81 % |
Karuna Therapeutics Inc | % of Total 1.77 % |
Acadia Pharmaceuticals | % of Total 1.71 % |
Biohaven Ltd | % of Total 1.49 % |
Amicus Therapeutics | % of Total 1.44 % |
Blueprint Medc/D | % of Total 1.43 % |
Arrowhead Pharmaceuticals Inc | % of Total 1.43 % |
Bridgebio Pharma | % of Total 1.43 % |
Moderna Inc | % of Total 1.42 % |
Ultragenyx Pharma | % of Total 1.36 % |
Index Sector Weightings
% of Total | |
---|---|
Biotechnology | % of Total 99.99 % |
Index data as of 12/31/2023. Index sector weightings and top holdings are subject to change.
View Daily Fund Holdings
Strategy and Benefits
You know that TRADING is different than investing. But the opportunity to take advantage of short-term trends is only won, if you get the direction right.
Whether you’re a bull or a bear, Direxion is with you. Our leveraged ETFs are powerful tools built to help you:
- Magnify your short-term perspective with daily 3X leverage
- Go where there’s opportunity, with bull and bear funds for both sides of the trade; and
- Stay agile – with liquidity to trade through rapidly changing markets
Leveraged and inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments.
Distributions
LABD Direxion Daily S&P Biotech Bear 3X Shares
Record Date | Ex Date | Pay Date | Income Dividend | Short-Term Capital Gain | Long-Term Capital Gain |
---|---|---|---|---|---|
12/22/2023 | 12/21/2023 | 12/29/2023 | 0.08463 | — | — |
09/20/2023 | 09/19/2023 | 09/26/2023 | 0.19152 | — | — |
06/22/2023 | 06/21/2023 | 06/28/2023 | 0.09985 | — | — |
03/22/2023 | 03/21/2023 | 03/28/2023 | 0.21822 | — | — |
12/21/2022 | 12/20/2022 | 12/28/2022 | 0.09179 | — | — |
Record Date12/22/2023 Ex Date12/21/2023 Pay Date12/29/2023 Income Dividend0.08463 Short-Term Capital Gain— Long-Term Capital Gain— Record Date09/20/2023 Ex Date09/19/2023 Pay Date09/26/2023 Income Dividend0.19152 Short-Term Capital Gain— Long-Term Capital Gain— Record Date06/22/2023 Ex Date06/21/2023 Pay Date06/28/2023 Income Dividend0.09985 Short-Term Capital Gain— Long-Term Capital Gain— Record Date03/22/2023 Ex Date03/21/2023 Pay Date03/28/2023 Income Dividend0.21822 Short-Term Capital Gain— Long-Term Capital Gain— Record Date12/21/2022 Ex Date12/20/2022 Pay Date12/28/2022 Income Dividend0.09179 Short-Term Capital Gain— Long-Term Capital Gain— |
LABU Direxion Daily S&P Biotech Bull 3X Shares
Record Date | Ex Date | Pay Date | Income Dividend | Short-Term Capital Gain | Long-Term Capital Gain |
---|---|---|---|---|---|
12/22/2023 | 12/21/2023 | 12/29/2023 | 0.20968 | — | — |
09/20/2023 | 09/19/2023 | 09/26/2023 | 0.00202 | — | — |
06/22/2023 | 06/21/2023 | 06/28/2023 | 0.00868 | — | — |
Record Date12/22/2023 Ex Date12/21/2023 Pay Date12/29/2023 Income Dividend0.20968 Short-Term Capital Gain— Long-Term Capital Gain— Record Date09/20/2023 Ex Date09/19/2023 Pay Date09/26/2023 Income Dividend0.00202 Short-Term Capital Gain— Long-Term Capital Gain— Record Date06/22/2023 Ex Date06/21/2023 Pay Date06/28/2023 Income Dividend0.00868 Short-Term Capital Gain— Long-Term Capital Gain— |
Documents
Fund Documents
- LABU LABD Fact Sheet (pdf)
- Direxion ETFs List (pdf)
- LABU Prospectus
- LABD Prospectus
- Daily Fund Holdings (csv)
Tax Documents
Download the following Tax Reporting Documents
- Form 8937
(LABD 2020)
How to Buy
ETFs are generally available for purchase on exchanges, much like stocks—and can be bought and sold throughout the trading day whenever exchanges are open. Direxion ETFs cannot be purchased directly from Direxion, but are available for trading on most trading platforms.
We strongly recommend that you take the time to educate yourself on how leveraged and inverse ETFs function and behave in various market conditions before you endeavor to trade them in your account. It’s always a good idea to consult a financial advisor or brokerage account representative if you have questions about any ETFs.
Please note, your advisor or broker may charge commissions or other transaction fees.If you have any questions specific to Direxion products, please contact us direct at [emailprotected] or 866-476-7523.